PE20140626A1 - Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona - Google Patents
Compuestos de bis(fluoroalquil)-1,4-benzodiazepinonaInfo
- Publication number
- PE20140626A1 PE20140626A1 PE2013002083A PE2013002083A PE20140626A1 PE 20140626 A1 PE20140626 A1 PE 20140626A1 PE 2013002083 A PE2013002083 A PE 2013002083A PE 2013002083 A PE2013002083 A PE 2013002083A PE 20140626 A1 PE20140626 A1 PE 20140626A1
- Authority
- PE
- Peru
- Prior art keywords
- bis
- benzodiazepinone
- fluoroalkyl
- compounds
- benzodiazepin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE BIS(FLUOROALQUIL)-1,4-BENZODIAZEPINONA DE FORMULA (I) DONDE R1 ES -CH2CF3 O -CH2CH2CF3; R2 ES -CH2CF3, -CH2CH2CF3 O -CH2CH2CH2CF3; R3 ES H O -CH3; Ra ES F, Cl, -CN, ENTRE OTROS; z ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: (2R,3S)-N-((3S)-1-METIL-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2,3-BIS(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; (2R,3S)-N-((3S)-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2,3-BIS(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; (2R,3S)-N-((3S)-1-METIL-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2-(2,2,2-TRIFLUOROETIL)-3-(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMA CRISTALINA Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE NOTCH SIENDO UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466238P | 2011-03-22 | 2011-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140626A1 true PE20140626A1 (es) | 2014-05-30 |
Family
ID=45894701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002083A PE20140626A1 (es) | 2011-03-22 | 2012-03-22 | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8629136B2 (es) |
| EP (1) | EP2688873B1 (es) |
| JP (1) | JP5873923B2 (es) |
| KR (1) | KR101948347B1 (es) |
| CN (1) | CN103717576B (es) |
| AR (1) | AR085471A1 (es) |
| AU (1) | AU2012230904B2 (es) |
| BR (1) | BR112013024059B1 (es) |
| CA (1) | CA2830902C (es) |
| CL (1) | CL2013002690A1 (es) |
| CO (1) | CO6771446A2 (es) |
| CY (1) | CY1116423T1 (es) |
| DK (1) | DK2688873T3 (es) |
| EA (1) | EA022530B1 (es) |
| ES (1) | ES2534080T3 (es) |
| HK (1) | HK1189218A1 (es) |
| HR (1) | HRP20150273T1 (es) |
| IL (1) | IL228534A (es) |
| MA (1) | MA35036B1 (es) |
| MX (1) | MX2013010420A (es) |
| MY (1) | MY161233A (es) |
| PE (1) | PE20140626A1 (es) |
| PL (1) | PL2688873T3 (es) |
| PT (1) | PT2688873E (es) |
| RS (1) | RS53843B1 (es) |
| SG (1) | SG193555A1 (es) |
| SI (1) | SI2688873T1 (es) |
| SM (1) | SMT201500091B (es) |
| TN (1) | TN2013000372A1 (es) |
| TW (1) | TWI530489B (es) |
| UY (1) | UY33961A (es) |
| WO (1) | WO2012129353A1 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029661T2 (en) | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| ES2707580T3 (es) | 2011-09-23 | 2019-04-04 | Oncomed Pharm Inc | Agentes de unión a VEGF/DLL4 y usos de los mismos |
| EP2897944B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| EP2897938B1 (en) * | 2012-09-21 | 2017-03-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| EP2897942B1 (en) | 2012-09-21 | 2016-08-31 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors |
| EP2897946B1 (en) * | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
| WO2014047374A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| US9133139B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | １，４−ベンゾジアゼピノン化合物のプロドラッグ |
| US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| WO2014165718A1 (en) * | 2013-04-04 | 2014-10-09 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| CN103435562B (zh) * | 2013-08-26 | 2016-02-24 | 华东理工大学 | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |
| JP6827415B2 (ja) * | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| CN104352488B (zh) * | 2014-10-31 | 2016-08-31 | 厦门大学 | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 |
| US10174015B2 (en) | 2014-10-31 | 2019-01-08 | Xiamen University | Substituted heterocyclic derivative, preparation method and use thereof |
| CN104356082B (zh) * | 2014-10-31 | 2016-07-13 | 厦门大学 | 一类取代杂环衍生物及其制备方法 |
| CN104892532B (zh) * | 2015-05-20 | 2017-09-08 | 成都理工大学 | 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺 |
| RU2738232C2 (ru) | 2015-07-22 | 2020-12-09 | Энанта Фармасьютикалс, Инк. | Производные бензодиазепина как ингибиторы rsv |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| US20170226129A1 (en) | 2016-01-15 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| CA3017411A1 (en) | 2016-03-15 | 2017-09-21 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| EP3438128B1 (en) * | 2017-08-04 | 2020-05-20 | Alzheimur 2012 S.L. | Anti-presenilin antibody for use in the prevention and/or treatment of cancer |
| WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
| WO2019094903A1 (en) * | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
| WO2019094920A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| US20210379079A1 (en) * | 2018-05-06 | 2021-12-09 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| MX2020011826A (es) * | 2018-05-06 | 2021-01-15 | Ayala Pharmaceuticals Inc | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |
| AU2019271151A1 (en) * | 2018-05-15 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| WO2019222231A1 (en) * | 2018-05-15 | 2019-11-21 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
| CA3101340A1 (en) * | 2018-05-24 | 2019-11-28 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| US11254664B2 (en) | 2019-03-18 | 2022-02-22 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| SG11202112061RA (en) * | 2019-05-15 | 2021-11-29 | Ayala Pharmaceuticals Inc | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer |
| WO2020261093A1 (en) | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| US11572367B2 (en) | 2019-10-04 | 2023-02-07 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| IL301060A (en) | 2020-09-03 | 2023-05-01 | Bristol Myers Squibb Co | Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepine compounds and their uses |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| MX2023009961A (es) | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| CN117794536A (zh) | 2021-06-02 | 2024-03-29 | 塞莱斯蒂亚生物技术股份公司 | 在治疗自身免疫性和炎症性疾病的方法中使用的化合物 |
| WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2250203A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| AU1618000A (en) | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| CN1636011A (zh) * | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬 |
| DE60007960T2 (de) | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
| AU7997700A (en) | 1999-10-08 | 2001-04-23 | Du Pont Pharmaceuticals Company | Amino lactam sulfonamides as inhibitors of abeta protein production |
| US20020048610A1 (en) * | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6756511B2 (en) | 2000-01-24 | 2004-06-29 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| CA2395862A1 (en) | 2000-02-17 | 2001-08-23 | Hong Liu | Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| EP1268454A1 (en) | 2000-03-31 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Succinoylamino heterocycles as inhibitors of a-beta protein production |
| CN1434803A (zh) | 2000-04-03 | 2003-08-06 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白质产生抑制剂的环内酰胺 |
| IL151576A0 (en) | 2000-04-03 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic lactams as inhibitors of a-beta protein production |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| AU2001257006A1 (en) | 2000-04-11 | 2001-10-23 | Du Pont Pharmaceuticals Company | Substituted lactams as inhibitors of abeta protein production |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| CA2379445C (en) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production |
| US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
| EA012387B1 (ru) | 2002-09-20 | 2009-10-30 | Эрроу Терапьютикс Лимитед | Производные бензодиазепина, содержащие их продукт и фармацевтическая композиция и их применение |
| ES2311795T3 (es) | 2003-02-04 | 2009-02-16 | F. Hoffmann-La Roche Ag | Derivados de malonamida como inhibidores de gamma-secretasa. |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| BRPI0413533A (pt) | 2003-09-09 | 2006-10-10 | Hoffmann La Roche | derivados de malonamida que bloqueiam a atividade de gama-secretase |
| EP1795198A1 (en) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
| EP2198863A1 (en) | 2006-02-27 | 2010-06-23 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| BRPI0709773B8 (pt) | 2006-03-27 | 2021-05-25 | Hoffmann La Roche | derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer |
| WO2008034735A2 (en) | 2006-09-20 | 2008-03-27 | F. Hoffmann-La Roche Ag | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| BRPI0815135A2 (pt) | 2007-08-14 | 2015-02-03 | Lilly Co Eli | Derivados de azepina como inibidores de gama secretase. |
| CA2710913A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Use of a gamma-secretase inhibitor for treating cancer |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
-
2012
- 2012-02-24 TW TW101106426A patent/TWI530489B/zh active
- 2012-03-21 AR ARP120100932A patent/AR085471A1/es not_active Application Discontinuation
- 2012-03-21 UY UY0001033961A patent/UY33961A/es active IP Right Grant
- 2012-03-22 MA MA36323A patent/MA35036B1/fr unknown
- 2012-03-22 EA EA201391324A patent/EA022530B1/ru not_active IP Right Cessation
- 2012-03-22 PE PE2013002083A patent/PE20140626A1/es active IP Right Grant
- 2012-03-22 BR BR112013024059-8A patent/BR112013024059B1/pt active IP Right Grant
- 2012-03-22 PL PL12711102T patent/PL2688873T3/pl unknown
- 2012-03-22 SI SI201230162T patent/SI2688873T1/sl unknown
- 2012-03-22 CN CN201280025022.2A patent/CN103717576B/zh active Active
- 2012-03-22 PT PT127111029T patent/PT2688873E/pt unknown
- 2012-03-22 KR KR1020137027347A patent/KR101948347B1/ko active IP Right Grant
- 2012-03-22 WO PCT/US2012/030021 patent/WO2012129353A1/en active Application Filing
- 2012-03-22 US US13/426,730 patent/US8629136B2/en active Active
- 2012-03-22 SG SG2013070743A patent/SG193555A1/en unknown
- 2012-03-22 JP JP2014501220A patent/JP5873923B2/ja active Active
- 2012-03-22 AU AU2012230904A patent/AU2012230904B2/en active Active
- 2012-03-22 ES ES12711102.9T patent/ES2534080T3/es active Active
- 2012-03-22 EP EP12711102.9A patent/EP2688873B1/en active Active
- 2012-03-22 MY MYPI2013003410A patent/MY161233A/en unknown
- 2012-03-22 RS RS20150150A patent/RS53843B1/en unknown
- 2012-03-22 MX MX2013010420A patent/MX2013010420A/es active IP Right Grant
- 2012-03-22 DK DK12711102T patent/DK2688873T3/en active
- 2012-03-22 CA CA2830902A patent/CA2830902C/en active Active
-
2013
- 2013-09-17 IL IL228534A patent/IL228534A/en active IP Right Grant
- 2013-09-17 CL CL2013002690A patent/CL2013002690A1/es unknown
- 2013-09-19 TN TNP2013000372A patent/TN2013000372A1/fr unknown
- 2013-09-20 CO CO13224494A patent/CO6771446A2/es unknown
- 2013-12-09 US US14/100,896 patent/US8822454B2/en active Active
-
2014
- 2014-01-30 HK HK14101033.1A patent/HK1189218A1/xx unknown
-
2015
- 2015-03-10 HR HRP20150273TT patent/HRP20150273T1/hr unknown
- 2015-04-13 SM SM201500091T patent/SMT201500091B/xx unknown
- 2015-04-17 CY CY20151100355T patent/CY1116423T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20210642A1 (es) | Inhibidores de pd-1/pd-l1 | |
| PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20110368A1 (es) | Moduladores de mif | |
| PE20151274A1 (es) | Inhibidores de erk y sus usos | |
| DOP2010000326A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20141702A1 (es) | Compuestos de carbamato y preparacion y uso de los mismos | |
| PE20160874A1 (es) | Compuestos quimicos | |
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20141050A1 (es) | Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
| EA201100037A1 (ru) | Органические соединения | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PE20141170A1 (es) | Moduladores del transporte nuclear que contienen hidrazida y sus usos | |
| EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| PE20171099A1 (es) | Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-diona como inhibidores de adamts para el tratamiento de osteoartritis | |
| PE20090210A1 (es) | Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |